Bruker AXS Launches New SuperSpeedSolutions-TM- for Materials Research and Nanostructure Applications.

Business Editors/Health/Medical Writers

MADISON, Wis.--(BUSINESS WIRE)--Jan. 13, 2004

Bruker AXS Inc., an operating company of Bruker BioSciences Corporation (Nasdaq: BRKR), announced today the launch of a new series of X-ray diffraction (XRD) systems for materials research applications, named SuperSpeedSolutions(TM). Two novel technologies, the high-power Turbo-X-ray Source(TM) and the high-speed VANTEC-1(TM) detector based on brand new MikroGap(TM) technology, now enable X-ray diffraction to go beyond current limitations in terms of sensitivity and speed. Bruker AXS is starting to ship first systems in Q1/04.

The new Turbo-X-ray Source has been developed at Bruker AXS' new Yokahama R&D center which originated from the acquisition of MAC Science in 2002. The Turbo-X-ray Source is fully integrated into the D8 platform and shows outstanding sensitivity compared with other systems in the market. In combination with the new VANTEC-1 detector, or the existing HISTAR(TM) detection system, it enables researchers to perform time-resolved X-ray diffraction experiments with milliseconds time resolution. The new SuperSpeedSolutions concept also includes systems for nanostructure analysis, by combining the recently launched NANOSTAR(TM) with the new Turbo-X-ray Source.

Frank Burgaezy, Managing Director and Business Unit Manager Materials Research, stated: "This is a major step forward in applying new X-ray technologies in the materials research market. In this 'three-continent' project our R&D teams in Madison, WI/USA, Karlsruhe/Germany and Yokohama/Japan have been working closely together, and the final outcome has even surpassed our highest expectations. We are proud that we can now offer the fastest and most sensitive X-ray laboratory diffraction system in the market, enabling our customers to tackle new applications in materials research and perform better and faster analyses on their current research targets."

Lutz Bruegemann, Marketing Manager for Materials Research, commented: "After demonstrating the outstanding analytical capabilities and the smart integration of our new SuperSpeedSolutions, we have so far received extremely positive feedback from our customers. Serving the entire materials research market from cutting-edge science to high-throughput industrial analysis, our SuperSpeedSolutions will not only extend our strong market position, but will also open new opportunities in market segments which were formerly not addressed by XRD."

Roger Durst, Vice President of R&D and Chief Technology Officer, added: "These exciting new products resulted from years of focused research by our global development team. We have married two powerful new technologies: our compact, high-intensity Turbo-X-ray Source delivers up to an order of magnitude more flux than conventional tubes while our breakthrough MikroGap detector technology features unprecedented quantum efficiency and counting rate performance. Together these tools allow existing experiments to be dramatically accelerated and also open up entirely new classes of time-resolved applications."

Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.